Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity…
By M. Macdonald, M. Petrie, Fumi Varyani, J. Ostergren, E. Michelson, James B. Young, S. Solomon, C. Granger, K. Swedberg, S. Yusuf and 2 more. European Heart Journal, 2008
633 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism
View Paper: https://www.semanticscholar.org/paper/97db47eb0104b15a32bc79bcba609f3a06b821e3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, neutral): “DM and ischaemic heart disease may interact to accelerate the deterioration of myocardial dysfunction, HF progression, and unfavourably influence prognosis.(179,180) † Although the relationship between elevated glucose level and a higher risk for HF is established in patients with DM, a direct benef”
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018, methodology): “CHARM trial, T2DM was an independent risk factor for both all-cause mortality and CV mortality even after adjustment for 32 co-variates (1).”
- Epidemiology and clinical course of heart failure with preserved ejection fraction (2011, background): “The presence of diabetes increases the likelihood of cardiovascular-related death in HFPEF.(60) Some recent investigations have evaluated if the paradigm of reverse epidemiology observed in HFREF is also evident in HFPEF.”